#United States #San Diego #Primrose Bio #Prima RNApols #mRNA Manufacturing

Primrose Bio Launches Prima RNApols™ ExTend

Primrose Bio, Inc., headquartered in San Diego, has unveiled its latest innovation—Prima RNApols™ ExTend, an advanced RNA polymerase specifically designed for the efficient manufacturing of long-template mRNA vaccines and therapeutics. This launch marks a significant milestone in the biotechnology sector, addressing persistent challenges in mRNA production with a focus on quality and cost-effectiveness.

Enhancing mRNA Quality

Traditionally, the production of long-template mRNAs has been fraught with integrity and quality issues, often leading to hindered drug development processes. The introduction of Prima ExTend directly addresses these concerns by significantly improving the quality of the synthesized mRNA. What sets this enzyme apart is its ability to reduce the presence of double-stranded RNA (dsRNA), a common byproduct in the mRNA manufacturing process that can complicate further purification steps.

Helge Zieler, CEO of Primrose Bio, emphasized the importance of this innovation in a recent statement, saying, "Prima ExTend is a much-needed innovation for the production of long-template mRNA therapeutics, that often struggle with integrity and quality issues that add risk to these programs." This systematic enhancement signals a new era for researchers and developers pursuing high-integrity, high-yield mRNA solutions.

Cost Reduction in Production

Beyond just improving quality, Prima RNApols™ ExTend also offers significant cost reductions in mRNA production. The enzyme’s enhanced transcription efficiency allows researchers to yield higher amounts of mRNA using fewer inputs. This means that companies looking to manufacture mRNA therapeutics can expect to lower their production costs significantly, creating a more sustainable approach to mRNA-based medicines.

Versatile Applications

The Prima RNApols ExTend is not only available as a stand-alone enzyme but also comes in an in vitro transcription kit, catering to various research applications. For organizations aiming to engage in clinical and commercial mRNA manufacturing, Primrose Bio offers GMP-grade Prima RNApols manufactured under ISO 13485:2016 certified quality systems.

This ensures that organizations can trust both the quality and efficacy of the enzyme for their therapeutic development needs, addressing regulatory demands while accelerating innovation.

Industry Recognition

Primrose Bio has established itself as a leader in the technological arena of therapeutic manufacturing. Their proprietary platforms are not only suited for mRNA technology but find applications across a range of drug manufacturing challenges. Major pharmaceutical companies, including Merck and Jazz Pharmaceuticals, leverage Primrose's technology to drive their research and development efforts forward.

As the landscape of drug manufacturing continues to evolve, innovations like Prima RNApols™ ExTend will be crucial in driving the development of future mRNA-based therapeutics and vaccines, contributing to better health outcomes globally.

For further information on Prima RNApols ExTend and other technologies offered by Primrose Bio, visit www.prima.primrosebio.com.

Conclusion

As we look to the future of mRNA therapeutics, technology providers like Primrose Bio are positioned at the forefront of innovation. With their launch of Prima RNApols™ ExTend, they are paving the way for more efficient, cost-effective, and high-quality mRNA manufacturing processes that hold the promise of transforming therapeutic development in the biopharmaceutical industry.